Transforming growth factor-beta 3(Tgf-beta3) in a collagen gel delays fusion of the rat posterior interfrontal suture in vivo.
Postnatal expansion of the intramembranous bones of the craniofacial skeleton occurs as bone growth at sutures. Loss of the bone growth site occurs when the suture fails to form, or when the newly formed sutures become ossified, resulting in premature obliteration. Previous experiments demonstrated that removal of dura mater from fetal rat coronal sutures, or neutralizing transforming growth factor-beta 2 (Tgf-beta2) activity using antibodies resulted in premature obliteration of the suture in vitro. Conversely, addition of Tgf-beta3 to coronal sutures in vitro rescued them from osseous obliteration. To examine whether Tgf-beta3 rescues sutures from obliteration in vivo, a collagen gel was used as a vehicle to deliver Tgf-beta3 to the normally fusing rat posterior interfrontal (IF) suture. Surgery was done on postnatal day 9 (P9) rats, in which collagen gels containing 0, 3, or 30 ng Tgf-beta3 were placed above the IF suture, underneath the periosteum for 2 weeks. By P24, 75-100% of animals in control unoperated, sham-operated, and collagen gel-only groups had fused IF sutures. In contrast, 40% of sutures exposed to 3 ng Tgf-beta3 remained open, while sutures exposed to 30 ng Tgf-beta were similar to controls. By immunohistochemistry, sutures rescued from obliteration by Tgf-beta3 had the same Tgf-beta receptor type II (Tbetar-II) distribution as controls. However, Tgf-beta3-treated sutures had altered Tgf-beta2 and Tbetar-I distribution compared to controls.
Opperman
Lynne A
LA
Department of Biomedical Sciences, Baylor College of Dentistry, Texas A&M University System Health Science Center, Dallas, TX 75266-0677, USA. opperman@tambcd.edu
Moursi
Amr M
AM
Sayne
Jennifer R
JR
Wintergerst
Ana Maria
AM
D000818:Animals; D000831:Animals, Newborn; D024042:Collagen Type I / Q000494:pharmacology*; D003393:Cranial Sutures / Q000187:drug effects* / Q000254:growth & development; D003398:Craniosynostoses / Q000378:metabolism / Q000517:prevention & control*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004337:Drug Carriers; D005624:Frontal Bone / Q000187:drug effects / Q000254:growth & development; D007124:Immunoenzyme Techniques; D051381:Rats; D017207:Rats, Sprague-Dawley; D018125:Receptors, Transforming Growth Factor beta / Q000378:metabolism; D016212:Transforming Growth Factor beta / Q000378:metabolism / Q000494:pharmacology*; D053781:Transforming Growth Factor beta2; D053782:Transforming Growth Factor beta3
D024042:Collagen Type I; D004337:Drug Carriers; D018125:Receptors, Transforming Growth Factor beta; C509046:Tgfb3 protein, rat; D016212:Transforming Growth Factor beta; D053781:Transforming Growth Factor beta2; D053782:Transforming Growth Factor beta3